This study aimed to identify the effects of different bisphosphonates in reducing skeletal-related events, and to determine whether there are any differences in their cost-effectiveness, taking into account their efficacy, safety profile and administration routes. A systematic literature search of databases, such as PubMed and the Cochrane Controlled Trials Register, supplemented by the latest congress abstracts from meetings of the European Hematology Association and the American Society of Clinical Oncology was conducted up to November 2006. Important references in reviews published by peer-reviewed journals were also taken into consideration. Our base-case cost-effectiveness analysis for Germany and the UK showed cost savings for oral clodronate therapy compared with other bisphosphonate therapies. In Germany, costs per patient of treatment with oral clodronate were €1092.38, €2360.40 and €2500.29 less than with oral ibandronate, intravenous pamidronate and intravenous zoledronate, respectively. The UK results were similar, the costs per patient of treatment with oral clodronate being €841.79, €2989.99 and €3669.19 less than with oral ibandronate, intravenous pamidronate and intravenous zoledronate, respectively.
RogersMJGordonSBenfordHL: Cellular and molecular mechanisms of action of bisphosphonates. Cancer2000; 88: 2961–2978.
4.
BrownJENeville-WebbeHColemanRE: The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer2004; 11: 207–224.
5.
PatersonAHPowlesTJKanisJA: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol1993; 11: 59–65.
6.
HortobagyiGNTheriaultRLPorterL for the Protocol 19 Aredia Breast Cancer Study Group: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med1996; 335: 1785–1791.
7.
BodyJJDielIJLichinitserMR: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol2003; 14: 1399–1405.
8.
CostaLLiptonAColemanRE: Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther2006; 3: 143–147.
9.
KanisJAPowlesTPatersonAH: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996; 19: 663–667.
10.
PavlakisNSchmidtRLStocklerM: Bisphosphonates for breast cancer. Cochrane Database Syst Rev2005; CD003474.
11.
De CockEHuttonJCanneyP: Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer2005; 13: 975–986.
12.
BottemanMBarghoutVStephensJ: Cost-effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol2006; 17: 1072–1082.
13.
GuestJFCleggJPDavieAM: Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Curr Med Res Opin2005; 21: 805–815.
14.
HillnerBEWeeksJCDeschCE: Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol2000; 18: 72–79.
15.
RosenLSGordonDKaminskiM: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003; 98: 1735–1744.
16.
TanvetyanonTStiffPJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol2006; 17: 897–907.
17.
NagyZ: Zoledronic acid (ZOMETA): A significant improvement in the bone metastases. Pathol Oncol Res2005; 11: 186–187.
18.
KristensenBEjlertsenBGroenvoldM: Oral clodronate in breast cancer patients with bone metastases: A randomized study. J Intern Med1999; 246: 67–74.
19.
Tubiana-HulinMBeuzebocPMauriacL: Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer2001; 88: 701–707.
20.
HultbornRGundersenSRydenS: Efficacy of pamidronate in breast cancer with bone metastases: A randomized, double-blind placebo-controlled multicenter study. Anticancer Res1999; 19: 3383–3392.
21.
TheriaultRLLiptonAHortobagyiGN for the Protocol 18 Aredia Breast Cancer Study Group: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J Clin Oncol1999; 17: 846–854.
22.
BodyJJDielIJLichinitzerM: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer2004; 90: 1133–1137.
23.
RosenLSGordonDHDuganWJr: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004; 100: 36–43.
24.
KohnoNAogiKMinamiH: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol2005; 23: 3314–3321.
25.
CletonFJvan Holten-VerzantvoortATBijvoetOL: Effect of long-term bisphosponate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results Cancer Res1989; 116: 73–78.
26.
ContePFGiannessiPGLatreilleJ: Delayed progression of bone metastases with pamodronate therapy in breast cancer patients: A randomized, multicenter phase III trial. Ann Oncol1994; 5: 41–44.
27.
HortobagyiGNTheriaultRLLiptonA for the Protocol 19 Aredia Breast Cancer Study Group: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol1998; 16: 2038–2044.
28.
DielIJMarschnerNKindlerM: Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases. Proc Annu Meet Am Soc Clin Oncol1999; abstract 488.
29.
FinnernHWSykesDP: The hospital cost of vertebral fractures in the EU: Estimates using national datasets. Osteoporos Int2003; 14: 429–436.
30.
Van Holten-VerzantvoortATKroonHMBijvoetOL: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol1993; 11: 491–498.
31.
AtulaSPowlesTPatersonA: Extended safety profile of oral clodronate after long term use in primary breast cancer patients. Drug Safety2003; 26: 661–671.
32.
ChangJTGreenLBeitzJ: Renal failure with the use of zoledronic acid. N Engl J Med2003; 349: 1676–1679.
33.
RosenLSGordonDKaminskiM: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J2001; 7: 377–387.
34.
Van den WyngaertTHuizingMTVermorkenJB: Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy?Ann Oncol2006; 17: 1197–1204.
35.
HoffAOTothBBAltundagK: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol2006; 24 (suppl): 8528 [abstract].
36.
DurieBGKatzMCrowleyJ: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med2005; 353: 99–102.
37.
DurieBGKatzMMcCoyJ: Osteonecrosis of the jaws in myeloma: Analysis of risk factors including time dependency of Aredia and Zometa use, steroid use and underlying dental problems. Haematologica2005; 90: 190 [abstract].
38.
WooSBHellsteinJWKalmarJR: Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med2006; 144: 753–761.
39.
DunstanCRFelsenbergDSeibelMJ: Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol2007; 4: 42–55.
40.
MehtaD (ed): British National Formulary, version 52. London: Pharmaceutical Press, September 2006.
41.
Rote Liste® Service, Frankfurt/Main: Rote Liste®, Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen). Aulendorf 2006.
42.
SmithASCunninghamSJ: Which factors influence willingness-to-pay for orthognathic treatment?Eur J Orthod2004; 26: 499–506.
43.
BornerMMSchoffskiPde WitR: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer2002; 38: 349–358.
